Plain-English translation of NCT06858319 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who have already participated in earlier clinical trials of , a new medication being tested for IgA nephropathy (a kidney disease where the immune system damages the kidneys). In this phase, researchers want to see how safe the medication is and how well patients tolerate it when they keep taking it over a longer period of time. The study is open-label, meaning both you and your doctors will know you're receiving the medication.
Earlier studies showed promise that this treatment might help IgA nephropathy patients, but doctors need to understand the long-term safety profile to make sure the medication doesn't cause unexpected problems over months or years of use.
You likely qualify if…
You likely don't qualify if…
You would receive injections of the medication under your skin every two weeks (a dose of 600 mg). You would visit the study clinic regularly so doctors can check your kidney function, monitor for side effects, and assess how well the treatment is working. The study involves multiple medical centers, so you would attend visits at your local participating site. Blood tests and other routine checks would be part of your follow-up care throughout your participation.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States